WallStSmart

Boston Scientific Corp (BSX)vsRLX Technology Inc (RLX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 470% more annual revenue ($20.61B vs $3.62B). RLX leads profitability with a 25.5% profit margin vs 17.3%. RLX trades at a lower P/E of 21.4x. BSX earns a higher WallStSmart Score of 71/100 (B).

BSX

Strong Buy

71

out of 100

Grade: B

Growth: 8.0Profit: 7.0Value: 5.3Quality: 5.5
Piotroski: 4/9

RLX

Strong Buy

68

out of 100

Grade: B-

Growth: 7.3Profit: 6.0Value: 7.0Quality: 7.8
Piotroski: 5/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXSignificantly Overvalued (-22.6%)

Margin of Safety

-22.6%

Fair Value

$46.16

Current Price

$53.93

$7.77 premium

UndervaluedFair: $46.16Overvalued
RLXUndervalued (+60.3%)

Margin of Safety

+60.3%

Fair Value

$6.14

Current Price

$2.10

$4.04 discount

UndervaluedFair: $6.14Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.8/10
EPS GrowthGrowth
100.0%10/10

Earnings expanding 100.0% YoY

Market CapQuality
$84.08B9/10

Large-cap with strong market position

PEG RatioValuation
0.688/10

Growing faster than its price suggests

Operating MarginProfitability
20.6%8/10

Strong operational efficiency at 20.6%

RLX5 strengths · Avg: 9.8/10
Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
46.8%10/10

Revenue surging 46.8% year-over-year

EPS GrowthGrowth
81.7%10/10

Earnings expanding 81.7% YoY

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Profit MarginProfitability
25.5%9/10

Keeps 26 of every $100 in revenue as profit

Areas to Watch

BSX0 concerns · Avg: 0/10

No major concerns identified

RLX1 concerns · Avg: 3.0/10
Return on EquityProfitability
5.9%3/10

ROE of 5.9% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.

Bull Case : RLX

The strongest argument for RLX centers on Price/Book, Revenue Growth, EPS Growth. Profitability is solid with margins at 25.5% and operating margin at 11.0%. Revenue growth of 46.8% demonstrates continued momentum.

Bear Case : BSX

No major red flags identified for BSX, but monitor valuation.

Bear Case : RLX

The primary concerns for RLX are Return on Equity.

Key Dynamics to Monitor

BSX profiles as a mature stock while RLX is a growth play — different risk/reward profiles.

RLX carries more volatility with a beta of 1.15 — expect wider price swings.

RLX is growing revenue faster at 46.8% — sustainability is the question.

RLX generates stronger free cash flow (192M), providing more financial flexibility.

Bottom Line

BSX scores higher overall (71/100 vs 68/100), backed by strong 17.3% margins and 11.6% revenue growth. RLX offers better value entry with a 60.3% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

RLX Technology Inc

CONSUMER DEFENSIVE · TOBACCO · China

RLX Technology Inc., researches, develops, manufactures, distributes and sells e-vapor products in the People's Republic of China. The company is headquartered in Beijing, China.

Visit Website →

Want to dig deeper into these stocks?